Main Navigation

COVID-19 pregnancy complications

Infected individuals are about 40% more likely to develop serious complications or die during pregnancy.

Pregnant individuals infected with SARS-CoV-2, the virus that causes COVID-19, are about 40% more likely to develop serious complications or die during pregnancy than those who aren’t infected with the virus, according to a nationwide study led by a University of Utah Health obstetrician.

The researchers concluded that the severity of COVID-19 symptoms is a key indicator of a heightened risk of pregnancy complications. This was particularly evident among the most severely ill people, who were three times more likely to develop pregnancy complications than those who tested negative or who were less affected by the disease.

PHOTO CREDIT: Charlie Ehlert/University of Utah Health

Individuals who are most severely affected by COVID-19 are three times more likely to develop pregnancy complications than those who tested negative or who were less affected by the disease, according to Torri D. Metz, M.D., a University of Utah maternal-fetal medicine specialist.

Download Full-Res Image

“We already knew that pregnant people are at higher risk for the complications of COVID-19 itself,” says Torri D. Metz, a maternal-fetal medicine specialist and associate professor of obstetrics and gynecology at U of U Health who led the multi-center effort. “Our research is among the first to find that infection with SARS-CoV-2 can elevate the risk of serious consequences related to the progression of common pregnancy complications such as developing high blood pressure, having postpartum bleeding or acquiring an infection other than SARS. This is why we need to make sure pregnant individuals are vaccinated.”

The study appears in the Feb. 7, 2022, issue of JAMA.

The researchers analyzed electronic medical records of 14,104 pregnant individuals treated at 17 medical centers nationwide that participate in the Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units (MFMU) Network between March 1, 2020, and Dec. 31, 2020.

About 2,350 of these individuals tested positive for SARS-CoV-2 during pregnancy or within six weeks of delivery. More than 13% of those who tested positive developed pregnancy complications during the study compared to 9% of those who tested negative. All five of the maternal deaths occurred in the SARS-CoV-2 positive group. In addition, the researchers found that:

Complications were more prevalent with moderate to severe COVID-19

Compared to those who had mild (flu-like) symptoms or were asymptomatic, pregnant individuals who had moderate or severe symptoms, requiring treatment with supplemental oxygen or ICU care, were about three times (26.1% vs. 9.2%) more likely to have serious pregnancy complications.

These problems included eclampsia, severe high blood pressure, kidney failure and other organ damage caused by high blood pressure, sepsis from infections other than SARS-CoV-2 and endometritis requiring prolonged administration of intravenous antibiotics.

Premature birth was more likely in infected individuals

SARS-CoV-2 infection was significantly associated with premature birth and NICU admission. However, maternal SARS-CoV-2 was not associated with any other adverse outcomes among newborns. In fact, only 1.2% of newborns tested positive for the virus before discharge.

People with certain characteristics were more likely to have complications

Individuals who tested positive and subsequently developed pregnancy complications were more likely to have a body mass index (BMI) of 30 or higher and identify as Hispanic or Black. These findings are consistent with other demographic findings among non-pregnant individuals infected with the virus, Metz says.

Pregnant individuals who had moderate or severe COVID-19 symptoms were also at significantly higher risk of cesarean birth (45.4% vs. 32.4%) than those without SARS-CoV-2. However, cesarean birth rates were similar among those who had mild symptoms or were asymptomatic compared with those without SARS-CoV-2.

“Some pregnant individuals who have COVID-19 are just too sick for us to attempt a vaginal birth,” Metz says. “In certain circumstances, such as the onset of preeclampsia, the fetus is also far less likely to tolerate it.”

Among the study’s limitations is that 80% of the SARS-CoV-2 infections were detected in the third trimester, hampering efforts to evaluate the effects of the virus on complications early in pregnancy.

The study was also conducted prior to the widespread availability of mRNA vaccines. However, Metz says, the new findings bolster the scientific rationale behind efforts to get individuals who are pregnant, or considering having a child, vaccinated.

“The complications of pregnancy we observed were mostly in people who had moderate to severe symptoms of COVID-19,” Metz says. “We know from other studies that vaccination prevents the most severe symptoms of the disease. So, this is just another piece of the puzzle that should encourage pregnant people to get vaccinated.”

The study, “Association of SARS-CoV-2 Infection with Serious Maternal Morbidity and Mortality from Obstetric Complications,” appears in the Feb. 7, 2022, issue of JAMA. It was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences.

In addition to U of U Health, institutions participating in this study include George Washington University, University of Alabama, Northwestern University, Brown University, University of Texas Medical Branch, University of Pittsburgh, Case Western University, University of North Carolina, The Ohio State University, Columbia University, University of Pennsylvania, the University of Texas Health Sciences Center-Houston and the University of Texas-Austin.

Conflicts of Interest: Torri D. Metz received personal fees and grants from Pfizer as well as grants from Gestvision; Brenna L. Hughes received personal fees from Merck; Hyagriv N. Simihan is an LLC co-founder of Naima Health and received personal fees from UptoDate outside of the current study; Alan T. N. Tita received grants from Pfizer; Maged Costantine reported a relationship with Baxter International, Momenta Pharmaxeuticals, Progenity, AMAG Pharmaceuticals and ObsEva. No other authors report any conflict of interest.